152 related articles for article (PubMed ID: 36516563)
1. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C).
Singh N; Madhira V; Hu C; Olex AL; Bergquist T; Fitzgerald KC; Huling JD; Patel RC; Singh JA
Semin Arthritis Rheum; 2023 Feb; 58():152149. PubMed ID: 36516563
[TBL] [Abstract][Full Text] [Related]
2. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
[TBL] [Abstract][Full Text] [Related]
3. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
[TBL] [Abstract][Full Text] [Related]
4. Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals.
England BR; Roul P; Yang Y; Kalil AC; Michaud K; Thiele GM; Sauer BC; Baker JF; Mikuls TR
Arthritis Rheumatol; 2021 Dec; 73(12):2179-2188. PubMed ID: 33955209
[TBL] [Abstract][Full Text] [Related]
5. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
[TBL] [Abstract][Full Text] [Related]
6. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Sparks JA; Wallace ZS; Seet AM; Gianfrancesco MA; Izadi Z; Hyrich KL; Strangfeld A; Gossec L; Carmona L; Mateus EF; Lawson-Tovey S; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Pons-Estel GJ; Isnardi CA; Berbotto GA; Hsu TY; D'Silva KM; Patel NJ; Kearsley-Fleet L; Schäfer M; Ribeiro SLE; Al Emadi S; Tidblad L; Scirè CA; Raffeiner B; Thomas T; Flipo RM; Avouac J; Seror R; Bernardes M; Cunha MM; Hasseli R; Schulze-Koops H; Müller-Ladner U; Specker C; Souza VA; Mota LMHD; Gomides APM; Dieudé P; Nikiphorou E; Kronzer VL; Singh N; Ugarte-Gil MF; Wallace B; Akpabio A; Thomas R; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Yazdany J;
Ann Rheum Dis; 2021 Sep; 80(9):1137-1146. PubMed ID: 34049860
[TBL] [Abstract][Full Text] [Related]
7. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis.
Shi Y; Wu Y; Ren Y; Jiang Y; Chen Y
Int J Rheum Dis; 2019 Aug; 22(8):1361-1370. PubMed ID: 31099191
[TBL] [Abstract][Full Text] [Related]
8. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States.
Raiker R; DeYoung C; Pakhchanian H; Ahmed S; Kavadichanda C; Gupta L; Kardeş S
Semin Arthritis Rheum; 2021 Oct; 51(5):1057-1066. PubMed ID: 34450504
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rituximab in resistant palindromic rheumatism: first report in literature.
Raghavan P; Sreenath S; Cherian S; Shenoy PD
Clin Rheumatol; 2019 Sep; 38(9):2399-2402. PubMed ID: 31076945
[TBL] [Abstract][Full Text] [Related]
11. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with Severe COVID-19 Among Patients with Rheumatoid Arthritis: A Large, Nationwide Electronic Health Record Cohort Study in the United States.
Ye Y; Yue X; Krueger WS; Wegrzyn LR; Maniccia AW; Winthrop KL; Kim SC
Adv Ther; 2023 Sep; 40(9):3723-3738. PubMed ID: 37338653
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
Wade SD; Kyttaris VC
Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
[TBL] [Abstract][Full Text] [Related]
14. A Machine Learning Approach to Identify Predictors of Severe COVID-19 Outcome in Patients With Rheumatoid Arthritis.
Burns SM; Woodworth TS; Icten Z; Honda T; Manjourides J
Pain Physician; 2022 Nov; 25(8):593-602. PubMed ID: 36375193
[TBL] [Abstract][Full Text] [Related]
15. Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study.
Michaud K; Pedro S; Wipfler K; Agarwal E; Katz P
Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1322-1331. PubMed ID: 33787086
[TBL] [Abstract][Full Text] [Related]
16. Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
Md Yusof MY; Iqbal K; Darby M; Lettieri G; Vital EM; Beirne P; Dass S; Emery P; Kelly C
Rheumatology (Oxford); 2020 Oct; 59(10):2838-2846. PubMed ID: 32065634
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with long-term persistence of rituximab in rheumatoid arthritis In clinical practice: RITAR Study.
Cañamares Orbis I; Merino Meléndez L; Llorente Cubas I; Benedí González J; García-Vicuña R; Morell Baladrón A; González-Álvaro I; Ramírez Herraiz E
Med Clin (Barc); 2020 Jul; 155(1):1-8. PubMed ID: 31848023
[TBL] [Abstract][Full Text] [Related]
18. Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab.
Melong Pianta Taleng CM; Lauper K; Gilbert B; Cunningham T; Guemara R; Brulhart L; Dan D; Courvoisier D; Finckh A
RMD Open; 2021 Dec; 7(3):. PubMed ID: 34862310
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Pablos JL; Galindo M; Carmona L; Lledó A; Retuerto M; Blanco R; Gonzalez-Gay MA; Martinez-Lopez D; Castrejón I; Alvaro-Gracia JM; Fernández Fernández D; Mera-Varela A; Manrique-Arija S; Mena Vázquez N; Fernandez-Nebro A; ;
Ann Rheum Dis; 2020 Dec; 79(12):1544-1549. PubMed ID: 32796045
[TBL] [Abstract][Full Text] [Related]
20. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
Md Yusof MY; Kabia A; Darby M; Lettieri G; Beirne P; Vital EM; Dass S; Emery P
Rheumatology (Oxford); 2017 Aug; 56(8):1348-1357. PubMed ID: 28444364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
